Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 5/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3584831 | 0.98 | MAOA (0.47) | MAOAHRH1SIGMAR1MAPT | |
| SCHEMBL3587599 | 0.98 | MAOA (0.47) | MAOAHRH1SIGMAR1MAPT | |
| SCHEMBL3589419 | 0.98 | MAOA (0.47) | MAOAHRH1SIGMAR1MAPT | |
| SCHEMBL3593183 | 0.98 | MAOA (0.47) | MAOAHRH1SIGMAR1MAPT | |
| SCHEMBL3587172 | 0.98 | MAOA (0.47) | MAOAHRH1SIGMAR1MAPT | |
| SCHEMBL3584588 | 0.98 | MAOA (0.47) | MAOAHRH1SIGMAR1MAPT | |
| SCHEMBL3593093 | 0.98 | MAOA (0.47) | MAOAHRH1SIGMAR1MAPT | |
| SCHEMBL3596268 | 0.98 | MAOA (0.47) | MAOAHRH1SIGMAR1MAPT | |
| SCHEMBL3588310 | 0.98 | MAOA (0.47) | MAOAHRH1SIGMAR1MAPT | |
| SCHEMBL3589087 | 0.98 | MAOA (0.47) | MAOAHRH1SIGMAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101784188-A | Alkynyl phenyl derivative compounds for the treatment of ophthalmic diseases and disorders | ACUCELA INC | 2010-07-21 | — | — | CN | disclosed |
| US-7741242-B2 | Prepared by crosslinking a homogenized an addition polymer containing units from an unsaturated aryl-containing glycidyl ether or ester and an unsaturated alcohol or carboxylic acid and a zero-valent Pd compound to physically deposit the Pd compound on the polymer; oxidizing alcohols to aldehydes | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2010-06-22 | — | — | US | disclosed |
| EP-1537913-B1 | PALLADIUM CATALYST COMPOSITION | WAKO PURE CHEMICAL INDUSTIES L (JP) | 2009-07-01 | — | — | EP | disclosed |
| EP-1687297-A4 | TRIAZINE DIMERS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | PROMETIC BIOSCIENCES INC (CA) | 2009-04-22 | — | — | EP | disclosed |
| EP-1881835-A1 | TRIAZINE COMPOUNDS AND COMPOSITIONS THEREOF FOR THE TREATMENT OF CANCERS | ProMetic BioSciences Inc. (CA) | 2008-01-30 | — | — | EP | disclosed |
| US-20070149528-A1 | Triazine dimers for the treatment of autoimmune diseases | PROMETIC PHARMA SMT LIMITED (GB) | 2007-06-28 | — | — | US | disclosed |
| WO-2006122431-A1 | TRIAZINE COMPOUNDS AND COMPOSITIONS THEREOF FOR THE TREATMENT OF CANCERS | PROMETIC BIOSCIENCES INC. (CA) | 2006-11-23 | — | — | WO | disclosed |
| US-20060178486-A1 | Propylene block copolymer | MITSUBISHI CHEMICAL CORPORATION (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1687297-A1 | TRIAZINE DIMERS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | Prometic Biosciences Inc. (CA) | 2006-08-09 | — | — | EP | disclosed |
| EP-1645576-A1 | PROPYLENE BLOCK COPOLYMER | Mitsubishi Chemical Corporation (JP) | 2006-04-12 | — | — | EP | disclosed |
| US-20060019822-A1 | Palladium catalyst composition | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1537913-A1 | PALLADIUM CATALYST COMPOSITION | Wako Pure Chemical Industies, Ltd. (JP) | 2005-06-08 | — | — | EP | disclosed |
| WO-2005049607-A1 | TRIAZINE DIMERS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | PROMETIC BIOSCIENCES INC. (CA) | 2005-06-02 | — | — | WO | disclosed |
| CN-1144802-A | Pyridazinone derivatives and processes for preparing the same | TANABE SEIYAKU CO (JP) | 1997-03-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149528-A1 | Triazine dimers for the treatment of autoimmune diseases | SSB, TLR5, ICOS | MAOA 1496/4885HRH1 264/4885SIGMAR1 4361/4885 |
| US-20060019822-A1 | Palladium catalyst composition | ODC1, NUDC, ADH1C | MAOA 1512/4885HRH1 2656/4885SIGMAR1 3068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.